Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced that clinical data on its lead product candidate, ANG1005, was selected for presentation as part of a Poster Highlights Session at the upcoming American Society of Clinical Oncology (ASCO) 50th Annual meeting which will take place May 30-June 3, 2014 in Chicago, IL.